GlassScriptPhysician profile
Lily Phouikham
NPI 1730408899
$755.41
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $260 · 2021: $273 · 2022: $37.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127.04 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $125.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $124.94 | 2019 | |
| Pfizer INC. | $98.54 | 2021 | |
| Novo Nordisk INC | $83.54 | 2019-2022 | |
| Amarin Pharma, INC. | $45.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.82 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $36.07 | 2021 | |
| Horizon Therapeutics Plc | $30.66 | 2021 | |
| Ibsa Pharma INC. | $15.74 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2020 | |
| Genentech USA, INC. | $12.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Phouikham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.